Giant cell arteritis – a changing entity

Friederike Kesten\textsuperscript{a}, Markus Aschwanden\textsuperscript{b}, Patrick Gubser\textsuperscript{c}, Katharina Glatz\textsuperscript{d}, Thomas Daikeler\textsuperscript{e}, Christoph Hess\textsuperscript{a, c}\textsuperscript{*}

\textsuperscript{a} Medical Outpatient Department, University Hospital Basel, Switzerland
\textsuperscript{b} Department of Angiology, University Hospital Basel, Switzerland
\textsuperscript{c} Immunobiology Laboratory, Department of Biomedicine, University Basel, Switzerland
\textsuperscript{d} Institute of Pathology, University Basel, Switzerland
\textsuperscript{e} Department of Rheumatology, University Hospital Basel, Switzerland

\section*{Summary}

Giant cell arteritis (GCA) is the most common of the vasculitis syndromes and, being a disease of the elderly, its incidence is increasing with the general ageing of the population. GCA is most feared for its early complications, namely blindness and stroke, resulting from inflammation and subsequent occlusion of ocular and extra cranial arteries, respectively. More recently, however, GCA has been recognised to also affect limb arteries and the aorta with a high prevalence. These newly recognised features of GCA pose diagnostic, therapeutic and prognostic challenges to treating physicians. Here, recent developments in the field of GCA are summarised and discussed.

\textbf{Key words:} Giant cell arteritis; large vessel vasculitis; duplex sonography

\section*{Introduction}

Giant cell arteritis (GCA) affects large and medium sized arteries and is the most prevalent of the systemic vasculitis syndromes [1, 2]. Inflammation of the vessel wall is characterised by infiltration of T-cells and macrophages, presence of eponymous giant cells, granulomatous lesions, intimal hyperplasia and destruction of elastic fibres (fig. 1) [3].

While a stone relief from ancient Egypt very likely depicts a blind harp player suffering from GCA (fig. 2), the first official case was published in 1932 by Horton, Magath and Brown. In their report an individual with blindness, tongue necrosis and jaw claudication is described, and the authors conclude that their patient may suffer from “a new form of arteritis affecting the temporal vessels ... which probably represents a new clinical syndrome” (Morbus Horton) [4].

GCA predominantly affects individuals over 50 years of age, with a current prevalence of approximately 20/100000 in Central Europe. Women are affected more frequently than men (3:1), and the incidence increases with age [5]. The triggering events of GCA remain unknown. Geographical differences as well as occasional familial clustering suggest environmental, infectious and/or genetic factors to play a role [2].

\section*{Clinical presentation and diagnostic approach}

In its best known form, GCA affects the external carotid artery and its major extra cranial branches, leading to the classical symptoms of temporal headache, scalp tenderness, jaw claudication and tender temporal arteries. A feared complication – occurring in up to 20% of patients – is ocular ischaemia with ensuing anterior ischaemic optic neuropathy, leading to irreversible vision loss in 10–15% [6]. Another potentially catastrophic manifestation is cerebral ischaemia with infarction, occurring with predilection in the vertebro-basilar territory [7].

A systemic inflammatory response is characteristic in patients with GCA, variably reflected by fever, malaise, anorexia, weight loss, anaemia, and thrombocytosis. High erythrocyte sedimentation rates (ESR)- and C-reactive protein (CRP)-levels are typically seen in patients with GCA, yet a normal ESR/CRP does not exclude the disease, partic-
ularly when other clinical findings support the diagnosis [8, 9]. Occurring in up to 60%, polymyalgia rheumatica is the most common musculoskeletal manifestation in patients with GCA [10, 11]. Inversely, GCA may be present more often (9–20%) than previously appreciated in patients with signs and symptoms characteristic of polymyalgia rheumatica [12]. The current view is that GCA and PMR are two different but frequently overlapping conditions [11]. However, patients with PMR associated with GCA often have more severe disease, reflected by significant laboratory abnormalities and pronounced constitutional symptoms [13]. A retrospective study aimed to define the characteristics that are predictive for evidence of vasculitis in temporal artery biopsy samples in patients presenting with isolated PMR. In that study, among patients <70 years of age and without cranial features of GCA, the risk of GCA was so low, that temporal artery biopsy could be safely avoided and patients treated with low dose corticosteroids as is done in patients with isolated (“pure”) PMR [14].

According to the Chapel Hill Consensus Conference, large vessel vasculitis syndromes include GCA and Takayasu arteritis [15]. ACR (American College of Rheumatology) criteria used to classify Takayasu arteritis are: age at disease onset <40 years, claudication of extremities, decreased brachial artery pulse, blood pressure difference >10 mm Hg between arms, bruit over subclavian arteries or aorta and arteriogram abnormality. ACR criteria used to classify GCA are summarised in table 1 [17]. As reflected by these criteria, important differences between the two entities clearly exist. Whilst Takayasu arteritis is typically seen in young women of Asian ancestry and predominantly affects the aorta and its first branches, GCA largely affects older patients with a Caucasian background, showing a clinical predominance for cranial symptoms [16]. However, and discussed in detail below, recent findings also suggest important overlap.

It is important to realize that both sensitivity and specificity of the ACR criteria in an unselected population (i.e. when used as diagnostic criteria) is very low. Only very recently, the ACR and European League against Rheumatism (EULAR) have launched an exciting prospective observational study with the goal to develop, for the first time, diagnostic criteria – and at the same time reassess the classification criteria – for primary vasculitis. Diagnostic and Classification Criteria for Primary Systemic Vasculitis...

**Figure 2**

Detail of the tomb relief “the blind harp-player”. In this stone relief from the 14th century B.C., a blind harp player (eyes closed) of advanced age, with a very prominent temporal artery and seemingly in pain (Polyomyalgia rheumatica?) is depicted (reproduced from Toellner R: Historia Medicinae, 1983, with permission of the publisher [Andreas und Andreas, Salzburg, Austria]).

**Figure 3**

Duplex Sonographic (DS) images from three distinct arterial segments. Arterial segment (A) is classified as “vasculitis”, with homogenous, hypoechoic wall broadening, segment (B) as “arteriosclerosis”, with eccentric, irregular plaques and acoustic shadowing, and segment (C) as “normal”, showing a thin homogenous intima/media layer.
For diagnosing ischaemic disease—

sonography on identified into its sensitivity large MRI non-specific or MRI to detecting GCA remained rather low [21–23]. Inflammation of limb arteries in patients with GCA sometimes the only manifestation of the disease—has been described sporadically since the 1970s [24]. Yet, only with the advent of modern imaging techniques such as DS, systematic evidence became available indicating that GCA is a systemic vasculitis affecting vessels well beyond the cranial arteries. Indeed, we and others have shown that DS-defined large vessel vasculitis of lower limb arteries is present in about 30% (!) of patients with newly diagnosed GCA [21, 25]. Thus, GCA can be a (near-)perfect mimic of atherosclerosis induced intermittent claudication [26, 27].

Positron emission tomography (PET)

PET-studies, and more recently PET/Computer Tomography (CT) studies have become a major tool for diagnosing large vessel vasculitis. Specifically, assessing 18F-fluoro-2-deoxy-D-glucose (FDG) uptake by PET is extremely helpful to assess vasculitic involvement of intrathoracic vessels (that cannot be visualized by DS) (fig. 4), and in cases of non-specific signs and symptoms compatible with large vessel vasculitis [28, 29]. Sensitivity and specificity of PET/CT to detect large vessel vasculitis in untreated patients is around 85% and 95%, respectively [28]. In steroid-treated patients sensitivity of PET studies decreases [30]. However, no data is available regarding the dose and time dependency of this effect, nor about the subgroup of patients that remains “PET-positive” despite long-term steroid-exposure.

Importantly, FDG-PET/CT-scan studies revealed aortitis—a feature classically ascribed to Takayasu arteritis—as being present in >80% of newly diagnosed GCA patients [31], and also identified GCA as a prominent cause for fever of unknown origin (FUO) in elderly patients [32, 33]. Limitations of PET studies include its low resolution (approx. 4 mm), and the fact that pronounced FDG uptake by the CNS prevents visualisation of cranial arteries.

Magnetic resonance imaging (MRI)

One Tesla MRI is not useful for the diagnosis of GCA because of its low sensitivity [34], but advances of MRI technique, with systems operating at field strengths of 3 Tesla and more, has increased its sensitivity and specificity for diagnosing vascular inflammation [35]. MRI has been shown to reliably identify cervical, extra- and intracranial vasculitis, as well as aortitis [36]. To date, however, the clinical usefulness of high field-strength MRI in the context of large vessel vasculitis remains restricted by its limited availability and high costs.

Aside these important methodological advances, careful clinical and translational findings, as well as exciting basic research data hold great promise to soon impact the management of patients with suspected or defined GCA:

On a population level, ischaemic complications were shown to more often occur in patients with a low systemic inflammatory response [37, 38]. In line with this clinical observation, in the subset of patients with ischaemic events, levels of the acute-phase inflammatory cytokine...
IL-6 – both within the temporal artery biopsy specimens and in the circulation – are decreased [39]. These data indicate that inflammation as reflected by an acute-phase response and vascular occlusion can be dissociated and may be characteristics of distinct variants among a GCA-spectrum of disease. Understanding the regulation of vascular inflammation in GCA at the molecular level and the genetic susceptibility of individual patients (see Refs. [40] and [41] for more detailed information) may therefore help to identify subgroups of patients, and eventually permit to develop more specific treatment modalities.

Consensus exists with regard to a key role of dendritic cells (DCs) – a cell type resident within the adventitia of the vessel wall and centrally involved in initiating adaptive immune responses – in triggering GCA [42]. DCs are thought to become activated by molecules that bind receptors that are recognising a group of “danger signals” – so called toll-like receptor ligands- that gain access to the vascular wall via the vasa vasorum. Upon activation, DCs secrete inflammatory mediators that are recruiting and activating CD4+ T-cells and macrophages. At least two distinct CD4+ T-cell subsets, namely Th1 and Th1 cells, promote vascular inflammation in GCA [43, 44]. Recently, we have identified a third subset of T-cells with a phenotype linked to immunosuppressive cellular characteristics (CD4+ FoxP3+) as being part of the inflammatory infiltrate in a subset of patients with GCA (Cantoni N., Hess C. et al., unpublished observation). Macrophages, activated by T-cells within the vessel wall, secrete pro-inflammatory cytokines such as IL-1 and IL-6, as well as tissue-destructing enzymes and reactive oxygen intermediates. Together this inflammatory process leads to intimal hyperplasia and disruption of vessel wall integrity. Whether CD4+ FoxP3+ T-cells promote fibrosis and occlusion of vessels – while inhibiting acute-phase cytokine secretion (such as IL-6) – remains to be determined. It is, however, tempting to speculate that GCA-patients with defined histopathological characteristics may eventually benefit from different treatment strategies.

**Therapy**

Glucocorticoids (unfortunately) still are the mainstay of therapy in patients with GCA. Failure to rapidly respond to steroid treatment in terms of resolution of symptoms and normalisation of inflammation should raise the question of an alternative diagnosis. While highly efficient in inducing remission, glucocorticoids cause severe side effects [47], and studies more precisely defining dose and duration of glucocorticoid based therapies in GCA should be a priority. Based on a metaanalysis of the published evidence, current EULAR guidelines suggest that the initially prescribed dose of prednisolone/prednisone should be 1 mg/kg body weight (not exceeding 60 mg/day) maintained for four weeks and tapered gradually thereafter [45]. If severe ischaemic complications – such as visual impairment or stroke – are present, 0.5–1 g of methylprednisolone is recommended to be administered intravenously for three days, followed by oral dosage/tapering. Due to the risk of irreversible ischaemic events, treatment with glucocorticoids should be started immediately upon strong clinical suspicion of GCA. Initiating treatment prior to a temporal artery biopsy is unlikely to significantly influence results if the biopsy is not delayed beyond 1–2 weeks into therapy [46]. Based on our experience the same may well be true for DS (unpublished observation).

In the absence of evidence for relapsing disease, the prednisolone/prednisone-dose should reach 10–15 mg/d by month 3, and 5 mg/d by month 6 after diagnosis. Prednisolone/prednisone should then be maintained at 5 mg/d for at least 12 months, whereupon further tapering – guided by symptoms, signs of inflammation and possibly secondary adrenal insufficiency – is indicated [47]. Importantly, however, GCA takes a relapsing course in approx. 40% of cases within the first two years after diagnosis. As at initial presentation, relapses are usually associated with a rise in ESR/CRP. Beyond two years after diagnosis recurrence of GCA becomes less likely, and five years after initial diagnosis recurrence is exceedingly rare. Thus – at least in its classic inflammatory form – GCA appears to eventually follow a self-limiting course [48].

A frustrating 86% (!) of all patients with GCA suffer from therapy (i.e. glucocorticoid) related adverse effects [47]. Steroid-sparing/Disease Modifying anti-Rheumatic Drugs (DMARD) have been tested in various studies aiming to optimise outcome while reducing glucocorticoid toxicity. However, with the exception of methotrexate (MTX), no DMARD has been shown to be unequivocally effective in the treatment of GCA [49–51]. MTX – if used at a proper dose and ensuring bioavailability (10–15 mg/week, preferably subcutaneously) confers a modest benefit in terms of reducing the cumulative steroid dose and is indicated in relapsing disease [49]. Of note, while the value of TNF-α blocking agents – such as etanercept or infliximab – in treating resistant cases remains to be determined, these biologicals were not generally successful in inducing or maintaining disease remission [52, 53]. Hopes are up for therapies targeting cytokines that have been firmly established to play a role in the inflammatory process of GCA, and first promising results from a series of GCA-cases treated with IL-6 blocking antibodies have recently been reported [54]. Once the diagnosis of GCA is established, disease activity should be monitored clinically as well as based on serial measurements of ESR/CRP. The role of imaging in assessing the course of the disease remains to be determined. In case of a suspected relapse, increasing the daily prednisolone/prednisone dose by 10–15 mg for a few weeks may be sufficient to control disease activity again. Patients who

### Table 1: ACR classification criteria for giant cell arteritis [13].

<table>
<thead>
<tr>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥50 years at disease onset</td>
</tr>
<tr>
<td>New onset of localised headache</td>
</tr>
<tr>
<td>Temporal artery tenderness or decreased temporal artery pulse</td>
</tr>
<tr>
<td>ESR ≥50 mm/hour</td>
</tr>
<tr>
<td>Biopsy: necrotising arteritis; mononuclear cell infiltrates or a granulomatous process with multinucleated giant cells</td>
</tr>
</tbody>
</table>

Presence of ≥3/5: sensitivity of 93% and specificity of 91% for distinguishing GCA from other primary vasculitis syndromes.
have discontinued therapy and experience a relapse (which is rather rare) [48], should probably be treated analogous to newly diagnosed patients (evidence lacking). Importantly, all patients should receive osteoporosis prophylaxis consisting of calcium, vitamin D3 and – if indicated based on a DEXA examination – bisphosphonates. Although no positive impact of anti-aggregation therapy on the risk of severe ischaemic complications has yet been formally demonstrated [9, 55–57], low dose aspirin (75–150 mg/day) is generally recommended for patients with GCA in the absence of contraindications [45, 55].

Prognosis

Visual loss and stroke occur (if so) early in the course of the disease [48]. Visual loss is usually irreversible, while the prognosis of cerebral ischaemia depends on the size and localisation of the affected area. The fact that inflammation of the aorta is a prominent feature of GCA has only recently become evident. Formation of aortic aneurysms seems to correlate with the initial inflammatory involvement of the aorta [36] and the presence of hypertension at the time of diagnosis [38]. Therefore, after diagnosis, patients should be periodically monitored for the existence of aneurysmal disease, in particular in those with hypertension and severe inflammatory response at the time of diagnosis. It is important for the management of patients to realise that aneurysms can arise several years after diagnosis – i.e. when other signs and symptoms of GCA have subsided [59]. Of note, this fact does not rule out the possibility of ongoing subclinical vessel wall inflammation. Irrespective of its pathophysiology, in a large population based cohort, thoracic aneurysms of the aorta were 17 times (!) more frequent in patients with GCA as compared to non-affected controls [60]. Patients in this cohort were not actively screened for aneurysms and the prevalence of aortic aneurysms in patients with a history of GCA might be even higher. Despite the increased risk of strokes generally early after the diagnosis of GCA and aortic aneurysms several years later (in the extended follow up of these patients), most population-based studies have not shown significantly increased mortality in GCA patients [61, 62].

8-point summary

- The prevalence of GCA is increasing
- GCA is an important cause of FUO among individuals >50 years of age
- GCA often affects the aorta and limb arteries
- Given the high prevalence of aortic and limb artery inflammation and its impact on the management of patients – DS and PET/CT screening are valid options
- Due to the probably increased incidence of (mainly thoracic) aneurysms of the aorta, GCA has an impact on patient care beyond the early phase of the disease
- Immediate glucocorticoid treatment remains the only means to prevent irreversible visual loss and other catastrophic ischaemic events in GCA
- Glucocorticoid treatment of patients with GCA is associated with dramatic morbidity (add MTX on first relapse), prevention/therapy of osteoporosis is imperative and low-dose aspirin recommended

Closing remarks

Novel aspects of GCA have emerged – yet many long standing problems remain. In order to meet the challenges posed by the changing entity “GCA”, prospective cohorts such as the “Basel Riesenzell-Arteritis Kohorte” (BARK) study – are important. Only through a systematic and prospective approach can we examine precisely how clinical and biological features of GCA relate to presentation, complications, treatment response and prognosis of this complex, feared and at the same time fascinating disease.

Acknowledgments: We would like to thank Martin Walter (University Hospital Bern, Switzerland) for providing PET study images.

Funding / potential competing interests: C.H. and P.G. are supported by the Swiss National Science Foundation (31003A_135677/1 and PB323630-128881, respectively), T.D. is supported by the FAG (‘Freiwillige Akademische Gesellschaft’) of Basel and by a bursary from the EULAR.

Authors’ contribution: * equal contribution

Correspondence: Professor Christoph Hess, MD PhD, University Hospital Basel, CH-4031 Basel, Switzerland, chess@uhbs.ch

References

Figure 1

**TAB histopathology picture from a GCA-patient.** Temporal artery biopsy with characteristic histological findings of active giant cell arteritis: The arterial wall shows a dense chronic lymphohistiocytic inflammatory infiltrate. A multinucleated giant cell (arrow) lies next to the disrupted elastic lamina (arrowhead). The intima in the lower half of the image is thickened. H&E, 400x
Figure 2

Detail of the tomb relief “the blind harp-player”. In this stone relief from the 14th century B.C., a blind harp player (eyes closed) of advanced age, with a very prominent temporal artery and seemingly in pain (Polymyalgia rheumatica?) is depicted (reproduced from Toellner R: Historia Medicinae, 1983, with permission of the publisher [Andreas und Andreas, Salzburg, Austria]).
Figure 3

Duplex Sonographic (DS) images from three distinct arterial segments. Arterial segment (A) is classified as “normal”, showing a thin homogenous intima/media layer, segment (B) as “arteriosclerosis”, with eccentric, irregular plaques and acoustic shadowing, and segment (C) as “vasculitis”, with homogenous, hypechoic wall broadening. Arrows identify the vessel wall.
Figure 4

Whole body $[^{18}F] $-FDG-PET studies. In Panel (A) a normal PET study is shown, in Panel (B) intense FDG uptake in the wall of numerous large vessels is indicative of extensive vasculitis.